STAT Plus: Argenx antibody drug improves symptoms in patients with myasthenia gravis

Argenx, a Belgian drug maker, said Tuesday that its experimental medicine improved the symptoms of patients with a rare neuromuscular disease, achieving the primary goal of a late-stage clinical trial.

The positive study results will enable Argenx to seek U.S. approval before the end of the year as a potentially new treatment for patients with generalized myasthenia gravis, a chronic and debilitating condition in which the body’s own antibodies disrupt the communication between nerve endings and muscles.

Continue to STAT Plus to read the full story…

Read Original Article: STAT Plus: Argenx antibody drug improves symptoms in patients with myasthenia gravis »